Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.

MLA

Chang-Ching Wei, et al. “Continuous Low-Dose Everolimus Shrinkage Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma: A 48-Month Follow-up Study.” Journal of Investigative Medicine (Sage Publications Inc.), vol. 67, no. 3, Mar. 2019, pp. 686–90. EBSCOhost, https://doi.org/10.1136/jim-2018-000865.

APA

Chang-Ching Wei, Jeng-Daw Tsai, Ji-Nan Sheu, Sung-Lang Chen, Teng-Fu Tsao, Sheng-Hui Yang, Jeng-Dau Tsai, Wei, C.-C., Tsai, J.-D., Sheu, J.-N., Chen, S.-L., Tsao, T.-F., Yang, S.-H., & Tsai, J.-D. (2019). Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study. Journal of Investigative Medicine (Sage Publications Inc.), 67(3), 686–690. https://doi.org/10.1136/jim-2018-000865

Chicago

Chang-Ching Wei, Jeng-Daw Tsai, Ji-Nan Sheu, Sung-Lang Chen, Teng-Fu Tsao, Sheng-Hui Yang, Jeng-Dau Tsai, et al. 2019. “Continuous Low-Dose Everolimus Shrinkage Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma: A 48-Month Follow-up Study.” Journal of Investigative Medicine (Sage Publications Inc.) 67 (3): 686–90. doi:10.1136/jim-2018-000865.